{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,9]],"date-time":"2026-10-09T16:29:33Z","timestamp":1791563373659,"version":"4.3.4"},"reference-count":53,"publisher":"Public Library of Science (PLoS)","issue":"2","license":[{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:sec id=\"sec001\">\n<jats:title>Objective<\/jats:title>\n<jats:p>To assess whether in adults with dyslipidemia, statins reduce cardiovascular events, mortality, and adverse effects when compared to fibrates.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec002\">\n<jats:title>Methods<\/jats:title>\n<jats:p>Systematic review and meta-analysis of head-to-head randomized trials of statin and fibrate monotherapy. MEDLINE, EMBASE, Cochrane, WHO International Controlled Trials Registry Platform, and ClinicalTrials.gov were searched through October 30, 2019. Trials that had a follow-up of at least 28 days, and reported mortality or a cardiovascular outcome of interest were eligible for inclusion. Efficacy outcomes were cardiovascular mortality and major cardiovascular events. Safety outcomes included myalgia, serious adverse effects, elevated serum creatinine, and elevated serum alanine aminotransferase. Odds ratios (OR) and 95% confidence intervals (CI) were estimated using the Mantel-Haenszel fixed-effect model, and heterogeneity was assessed using the I<jats:sup>2<\/jats:sup> statistic.<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec003\">\n<jats:title>Results<\/jats:title>\n<jats:p>We included 19 eligible trials that directly compared statin and fibrate monotherapy and reported mortality or a cardiovascular event. Studies had a limited duration of follow-up (range 10 weeks to 2 years). We did not find any evidence of a difference between statins and fibrates for cardiovascular mortality (OR 2.35, 95% CI 0.94\u20135.86, I<jats:sup>2<\/jats:sup> = 0%; ten studies, n = 2657; low certainty), major cardiovascular events (OR 1.15, 95% CI 0.80\u20131.65, I<jats:sup>2<\/jats:sup> = 13%; 19 studies, n = 7619; low certainty), and myalgia (OR 1.32, 95% CI 0.95\u20131.83, I<jats:sup>2<\/jats:sup> = 0%; ten studies, n = 6090; low certainty). Statins had less serious adverse effects (OR 0.57, 95% CI 0.36\u20130.91, I<jats:sup>2<\/jats:sup> = 0%; nine studies, n = 3749; moderate certainty), less elevations in serum creatinine (OR 0.17, 95% CI 0.08\u20130.36, I<jats:sup>2<\/jats:sup> = 0%; six studies, n = 2553; high certainty), and more elevations in alanine aminotransferase (OR 1.43, 95% CI 1.03\u20131.99, I<jats:sup>2<\/jats:sup> = 44%; seven studies, n = 5225; low certainty).<\/jats:p>\n<\/jats:sec>\n<jats:sec id=\"sec004\">\n<jats:title>Conclusions<\/jats:title>\n<jats:p>The eligible randomized trials of statins versus fibrates were designed to assess short-term lipid outcomes, making it difficult to have certainty about the direct comparative effect on cardiovascular outcomes and mortality. With the exception of myalgia, use of a statin appeared to have a lower incidence of adverse effects compared to use of a fibrate.<\/jats:p>\n<\/jats:sec>","DOI":"10.1371\/journal.pone.0246480","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T22:22:53Z","timestamp":1612909373000},"page":"e0246480","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparative efficacy and safety of statin and fibrate monotherapy: A systematic review and meta-analysis of head-to-head randomized controlled trials"],"prefix":"10.1371","volume":"16","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7895-198X","authenticated-orcid":true,"given":"Joseph E.","family":"Blais","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria Kin Yi","family":"Tong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1793-1800","authenticated-orcid":true,"given":"Swathi","family":"Pathadka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Mok","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ian C. K.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esther W.","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2021,2,9]]},"reference":[{"issue":"2","key":"pone.0246480.ref001","article-title":"National trends in nonstatin use and expenditures among the US adult population from 2002 to 2013: insights from","volume":"7","author":"JA Salami","year":"2018","journal-title":"Medical Expenditure Panel Survey. J Am Heart Assoc"},{"issue":"17","key":"pone.0246480.ref002","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1016\/j.jacc.2015.08.042","article-title":"Trends in the use of nonstatin lipid-lowering therapy among patients with coronary heart disease: a retrospective cohort study in the Medicare population 2007 to 2011","volume":"66","author":"V Bittner","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"pone.0246480.ref003","article-title":"Trends in lipid-modifying agent use in 83 countries","author":"JE Blais","year":"2021","journal-title":"medRxiv [Preprint]"},{"key":"pone.0246480.ref004","article-title":"Fibrates for primary prevention of cardiovascular disease events","volume":"11","author":"T Jakob","year":"2016","journal-title":"Cochrane Database Syst Rev"},{"key":"pone.0246480.ref005","article-title":"Effects of fibrates on cardiovascular outcomes: a systematic review and meta-analysis","volume":"375","author":"M Jun","year":"2010","journal-title":"Lancet"},{"key":"pone.0246480.ref006","doi-asserted-by":"crossref","first-page":"g4379","DOI":"10.1136\/bmj.g4379","article-title":"Effect on cardiovascular risk of high density lipoprotein targeted drug treatments niacin, fibrates, and CETP inhibitors: meta-analysis of randomised controlled trials including 117 411 patients","volume":"349","author":"D Keene","year":"2014","journal-title":"BMJ"},{"issue":"15","key":"pone.0246480.ref007","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1001\/jama.2018.2525","article-title":"Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis","volume":"319","author":"EP Navarese","year":"2018","journal-title":"JAMA"},{"issue":"12","key":"pone.0246480.ref008","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1001\/jama.2016.13985","article-title":"Association between lowering LDL-C and cardiovascular risk reduction among different therapeutic interventions: a systematic review and meta-analysis","volume":"316","author":"MG Silverman","year":"2016","journal-title":"JAMA"},{"key":"pone.0246480.ref009","first-page":"CD009580","article-title":"Fibrates for secondary prevention of cardiovascular disease and stroke","volume":"10","author":"D Wang","year":"2015","journal-title":"Cochrane Database Syst Rev"},{"issue":"6","key":"pone.0246480.ref010","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1016\/S0895-4356(97)00049-8","article-title":"The results of direct and indirect treatment comparisons in meta-analysis of randomized controlled trials","volume":"50","author":"HC Bucher","year":"1997","journal-title":"J Clin Epidemiol"},{"key":"pone.0246480.ref011","volume-title":"Handbook for grading the quality of evidence and the strength of recommendations using the GRADE approach GRADE Working Group","author":"H Sch\u00fcnemann","year":"2013"},{"key":"pone.0246480.ref012","volume-title":"Cochrane Handbook for Systematic Reviews of Interventions Version 5.1.0","author":"J Higgins","year":"2011"},{"issue":"6","key":"pone.0246480.ref013","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.1016\/j.amjcard.2006.11.016","article-title":"Safety considerations with fibrate therapy","volume":"99","author":"MH Davidson","year":"2007","journal-title":"Am J Cardiol"},{"issue":"2","key":"pone.0246480.ref014","doi-asserted-by":"crossref","first-page":"e38","DOI":"10.1161\/ATV.0000000000000073","article-title":"Statin safety and associated adverse events: a scientific statement from the American Heart Association","volume":"39","author":"CB Newman","year":"2019","journal-title":"Arterioscler Thromb Vasc Biol"},{"issue":"7501","key":"pone.0246480.ref015","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1136\/bmj.38446.498542.8F","article-title":"Optimal search strategies for retrieving scientifically strong studies of treatment from Medline: analytical survey","volume":"330","author":"RB Haynes","year":"2005","journal-title":"BMJ"},{"issue":"1","key":"pone.0246480.ref016","first-page":"41","article-title":"Developing optimal search strategies for detecting clinically sound treatment studies in EMBASE","volume":"94","author":"SSL Wong","year":"2006","journal-title":"J Med Libr Assoc"},{"key":"pone.0246480.ref017","doi-asserted-by":"crossref","first-page":"d8141","DOI":"10.1136\/bmj.d8141","article-title":"Impact of document type on reporting quality of clinical drug trials: a comparison of registry reports, clinical study reports, and journal publications","volume":"344","author":"B Wieseler","year":"2012","journal-title":"BMJ"},{"issue":"1","key":"pone.0246480.ref018","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1186\/s12916-015-0430-4","article-title":"Comparison of serious adverse events posted at ClinicalTrials.gov and published in corresponding journal articles","volume":"13","author":"E Tang","year":"2015","journal-title":"BMC Medicine"},{"key":"pone.0246480.ref019","doi-asserted-by":"crossref","first-page":"d5928","DOI":"10.1136\/bmj.d5928","article-title":"The Cochrane Collaboration\u2019s tool for assessing risk of bias in randomised trials","volume":"343","author":"JPT Higgins","year":"2011","journal-title":"BMJ"},{"key":"pone.0246480.ref020","volume-title":"Review Manager (RevMan)","year":"2014"},{"issue":"2","key":"pone.0246480.ref021","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1136\/eb-2018-102911","article-title":"Practical guide to the meta-analysis of rare events","volume":"21","author":"O Efthimiou","year":"2018","journal-title":"Evid Based Ment Health"},{"issue":"8","key":"pone.0246480.ref022","doi-asserted-by":"crossref","first-page":"e010983","DOI":"10.1136\/bmjopen-2015-010983","article-title":"Impact of including or excluding both-armed zero-event studies on using standard meta-analysis methods for rare event outcome: a simulation study","volume":"6","author":"J Cheng","year":"2016","journal-title":"BMJ Open"},{"key":"pone.0246480.ref023","unstructured":"GRADEpro GDT: GRADEpro Guideline Development Tool. McMaster University; 2015 (developed by Evidence Prime, Inc.)."},{"issue":"1","key":"pone.0246480.ref024","first-page":"7","article-title":"Efficacy of pravastatin and bezafibrate in primary hypercholesterolaemia","volume":"116","author":"HR Arntz","year":"1991","journal-title":"Deutsche Medizinische Wochenschrift"},{"issue":"1","key":"pone.0246480.ref025","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1016\/0002-9149(92)90671-K","article-title":"A comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia","volume":"69","author":"RB D\u2019Agostino","year":"1992","journal-title":"Am J Cardiol"},{"issue":"3","key":"pone.0246480.ref026","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1097\/00005344-199903000-00018","article-title":"Effects of lipid-lowering drugs on left ventricular function and exercise tolerance in dyslipidemic coronary patients","volume":"33","author":"M de Lorgeril","year":"1999","journal-title":"J Cardiovasc Pharmacol"},{"issue":"6","key":"pone.0246480.ref027","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1111\/1755-5922.12148","article-title":"New fixed-dose combinations of fenofibrate\/simvastatin therapy significantly improve the lipid profile of high-risk patients with mixed dyslipidemia versus monotherapies","volume":"33","author":"C Foucher","year":"2015","journal-title":"Cardiovasc Ther"},{"issue":"4","key":"pone.0246480.ref028","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1016\/j.amjcard.2008.10.025","article-title":"Efficacy and safety of ABT-335 (fenofibric acid) in combination with atorvastatin in patients with mixed dyslipidemia","volume":"103","author":"AC Goldberg","year":"2009","journal-title":"Am J Cardiol"},{"issue":"6A","key":"pone.0246480.ref029","doi-asserted-by":"crossref","first-page":"55S","DOI":"10.1016\/0002-9343(94)90233-X","article-title":"Treatment of primary hypercholesterolemia: fluvastatin versus bezafibrate","volume":"96","author":"H Greten","year":"1994","journal-title":"Am J Med"},{"issue":"1","key":"pone.0246480.ref030","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.atherosclerosis.2008.09.027","article-title":"Efficacy and safety of ABT-335 (fenofibric acid) in combination with rosuvastatin in patients with mixed dyslipidemia: a phase 3 study","volume":"204","author":"PH Jones","year":"2009","journal-title":"Atherosclerosis"},{"issue":"5","key":"pone.0246480.ref031","first-page":"311","article-title":"Low-dose simvastatin or pravastatin in the treatment of moderate hypercholesterolemia: a comparison with bezafibrate","volume":"5","author":"CJ Lintott","year":"1995","journal-title":"Cardiovascular Risk Factors"},{"issue":"1","key":"pone.0246480.ref032","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.ahj.2008.08.027","article-title":"Efficacy and safety of ABT-335 (fenofibric acid) in combination with simvastatin in patients with mixed dyslipidemia: a phase 3, randomized, controlled study","volume":"157","author":"SM Mohiuddin","year":"2009","journal-title":"Am Heart J"},{"key":"pone.0246480.ref033","first-page":"135","article-title":"A one-year comparison of pravastatin and a fibrate in almost 2500 patients with complicated primary hyperlipidaemia","volume":"6","author":"GM Pover","year":"1995","journal-title":"British Journal of Clinical Research"},{"issue":"5\u20136","key":"pone.0246480.ref034","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1007\/s10557-010-6266-4","article-title":"Efficacy and safety of rosuvastatin 5 mg in combination with fenofibric acid 135 mg in patients with mixed dyslipidemia\u2014a phase 3 study","volume":"24","author":"EM Roth","year":"2010","journal-title":"Cardiovasc Drugs Ther"},{"issue":"4","key":"pone.0246480.ref035","first-page":"251","article-title":"The comparative treatment with lovastatin and bezafibrate of primary hypercholesterolemia. A randomized and double-blind trial","volume":"44","author":"J S\u00e1nchez Dom\u00ednguez","year":"1991","journal-title":"Rev Esp Cardiol"},{"issue":"8","key":"pone.0246480.ref036","doi-asserted-by":"crossref","first-page":"1644","DOI":"10.1253\/circj.CJ-10-0079","article-title":"Comparative study of bezafibrate and pravastatin in patients with coronary artery disease and high levels of remnant lipoprotein","volume":"74","author":"K Sano","year":"2010","journal-title":"Circ J"},{"issue":"11","key":"pone.0246480.ref037","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1093\/oxfordjournals.eurheartj.a060769","article-title":"Atherogenic risk reduction in patients with dyslipidaemia comparison between bezafibrate and lovastatin","volume":"16","author":"H Sinzinger","year":"1995","journal-title":"Eur Heart J"},{"issue":"2","key":"pone.0246480.ref038","first-page":"163","article-title":"The risk of ischaemic stroke during the fluvastatine and fenofibrate treatment","volume":"70","author":"D Skoloudik","year":"2007","journal-title":"Ceska a slovenska neurologie a neurochirurgie"},{"issue":"2","key":"pone.0246480.ref039","doi-asserted-by":"crossref","first-page":"186","DOI":"10.1016\/0149-2918(95)80018-2","article-title":"Effects of simvastatin versus gemfibrozil on lipids and glucose control in patients with non-insulin-dependent diabetes mellitus","volume":"17","author":"NIDDM Study Group","year":"1995","journal-title":"Clin Ther"},{"issue":"15","key":"pone.0246480.ref040","doi-asserted-by":"crossref","first-page":"35J","DOI":"10.1016\/0002-9149(88)90005-7","article-title":"Comparison between lovastatin and gemfibrozil in the treatment of primary hypercholesterolemia: the Finnish Multicenter Study","volume":"62","author":"MJ Tikkanen","year":"1988","journal-title":"Am J Cardiol"},{"issue":"1","key":"pone.0246480.ref041","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/0002-9343(93)90114-5","article-title":"Pravastatin and gemfibrozil alone and in combination for the treatment of hypercholesterolemia","volume":"94","author":"O Wiklund","year":"1993","journal-title":"Am J Med"},{"issue":"Suppl 4","key":"pone.0246480.ref042","first-page":"50","article-title":"Safety, tolerability, and efficacy of simvastatin and fenofibrate\u2013a multicenter study","volume":"77","author":"Simvastatin-Fenofibrate Study Group","year":"1990","journal-title":"Cardiology"},{"key":"pone.0246480.ref043","unstructured":"ClinicalTrials.gov. Identifier NCT00300482, Evaluate safety and efficacy of ABT-335 in combination with rosuvastatin calcium in subjects with multiple abnormal lipid levels in the blood [Internet]. Bethesda (MD): National Library of Medicine (US);.https:\/\/clinicaltrials.gov\/show\/NCT00300482."},{"key":"pone.0246480.ref044","unstructured":"ClinicalTrials.gov. Identifier NCT00300469, Evaluate safety and efficacy of ABT-335 in combination with atorvastatin in subjects with multiple abnormal lipid levels in the blood [Internet]. Bethesda (MD): National Library of Medicine (US);. https:\/\/clinicaltrials.gov\/show\/NCT00300469."},{"issue":"2","key":"pone.0246480.ref045","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1097\/FJC.0b013e318202709f","article-title":"Fibrates effect on cardiovascular risk is greater in patients with high triglyceride levels or atherogenic dyslipidemia profile: a systematic review and meta-analysis","volume":"57","author":"E Bruckert","year":"2011","journal-title":"J Cardiovasc Pharmacol"},{"issue":"2","key":"pone.0246480.ref046","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.atherosclerosis.2011.04.020","article-title":"Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis","volume":"217","author":"M Lee","year":"2011","journal-title":"Atherosclerosis"},{"issue":"16","key":"pone.0246480.ref047","doi-asserted-by":"crossref","first-page":"1308","DOI":"10.1161\/CIRCULATIONAHA.119.041998","article-title":"Association between triglyceride lowering and reduction of cardiovascular risk across multiple lipid-lowering therapeutic classes","volume":"140","author":"NA Marston","year":"2019","journal-title":"Circulation"},{"issue":"4","key":"pone.0246480.ref048","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1016\/j.jacl.2018.04.006","article-title":"Variations in time to benefit among clinical trials of cholesterol-lowering drugs","volume":"12","author":"PJ Barter","year":"2018","journal-title":"J Clin Lipidol"},{"issue":"9493","key":"pone.0246480.ref049","doi-asserted-by":"crossref","first-page":"1267","DOI":"10.1016\/S0140-6736(05)67394-1","article-title":"Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90\u2008056 participants in 14 randomised trials of statins","volume":"366","author":"Cholesterol Treatment Trialists\u2019 (CTT) Collaborators","year":"2005","journal-title":"Lancet"},{"issue":"9841","key":"pone.0246480.ref050","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/S0140-6736(12)60367-5","article-title":"The effects of lowering LDL cholesterol with statin therapy in people at low risk of vascular disease: meta-analysis of individual data from 27 randomised trials","volume":"380","author":"B Mihaylova","year":"2012","journal-title":"Lancet"},{"issue":"5","key":"pone.0246480.ref051","doi-asserted-by":"crossref","first-page":"943","DOI":"10.1016\/j.ahj.2007.07.011","article-title":"The role of fibrates in the prevention of cardiovascular disease\u2014a pooled meta-analysis of long-term randomized placebo-controlled clinical trials","volume":"154","author":"SA Saha","year":"2007","journal-title":"Am Heart J"},{"issue":"20","key":"pone.0246480.ref052","doi-asserted-by":"crossref","first-page":"2061","DOI":"10.1016\/j.jacc.2012.07.049","article-title":"Effects of fibrates in kidney disease: a systematic review and meta-analysis","volume":"60","author":"M Jun","year":"2012","journal-title":"J Am Coll Cardiol"},{"issue":"22 SUPPL. 1","key":"pone.0246480.ref053","first-page":"A11958","article-title":"Pitavastatin, but not bezafibrate, decreases carotic intima-media thickness in patients with type IIb hyperlipidemia (pitavastatin or bezafibrate intervention, assessment of antiarteriosclerotic effect, PIONEER study)","volume":"128","author":"S Yamashita","year":"2018","journal-title":"Circulation"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0246480","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T22:23:37Z","timestamp":1612909417000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0246480"}},"subtitle":[],"editor":[{"given":"James M","family":"Wright","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2021,2,9]]},"references-count":53,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2021,2,9]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0246480","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,9]]}}}